James Maher, MD
Gastroenterology · Houston, TXNPI 1497743165
Payments from drug & device makers
Across 946 payments — averaging $5621.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$2.6M
- Eli Lilly$738K
- Ironwood Pharmaceuticals, Inc$679K
- Genentech, Inc.$381K
- Boehringer Ingelheim International GmbH$292K
- AbbVie$231K
- plus $354K from 27 others
Across 8 payments — averaging $23,108 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celltrion, Inc.$175K
- Eli Lilly$10K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 100 | $2,644,069 |
| Eli Lilly | 41 | $738,131 |
| Ironwood Pharmaceuticals, Inc | 45 | $678,750 |
| Genentech, Inc. | 61 | $381,185 |
| Boehringer Ingelheim International GmbH | 204 | $291,799 |
| AbbVie(2 entities) | 100 | $230,856 |
| Pfizer | 35 | $82,307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 64 | $78,256 |
| Novo Nordisk AS | 87 | $47,167 |
| Shire North American Group Inc | 20 | $40,340 |
| Bristol Myers Squibb | 16 | $37,625 |
| Braintree Laboratories, Inc. | 11 | $23,610 |
| AstraZeneca | 2 | $19,344 |
| GSK | 3 | $13,500 |
| Ferring International Pharmascience Center US | 1 | $7,833 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 82 | $1,216 |
| Abbott | 2 | $530 |
| Janssen Research & Development, LLC | 1 | $500 |
| Johnson & Johnson | 19 | $337 |
| Romark Laboratories, LC | 9 | $160 |
| Phathom Pharmaceuticals, Inc. | 8 | $159 |
| Nestle Healthcare Nutrition Inc. | 8 | $144 |
| Redhill Biopharma Inc. | 8 | $134 |
| Lilly USA, LLC | 3 | $75 |
| Gilead | 3 | $53 |
| Celltrion USA Inc. | 3 | $51 |
| Sanofi | 2 | $43 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Evoke Pharma, Inc. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
How this compares
$5,318,334 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Houston
- Mazen NoureddinHouston$6.1M
- Uma MohanHouston$5M
- John VierlingHouston$2.8M
- Bincy AbrahamHouston$2.5M
- Jason HouHouston$2.3M
- Jignesh ShahHouston$1.7M
- Mouhamad Al-SabbaghHouston$1.6M
- Mohamed OthmanHouston$1.6M
- Harry OjeasHouston$1.5M
- Stephen PappasHouston$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.